DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Optimal Effect-site Concentration of Remifentanil for Inhibiting Response to Laryngeal Mask Airway (LMA) Removal

Information source: Yeungnam University College of Medicine
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Respiratory Complication

Intervention: Remifentanil (Drug)

Phase: N/A

Status: Completed

Sponsored by: Sangjin Park

Official(s) and/or principal investigator(s):
sangjin park, M.D., Principal Investigator, Affiliation: Department of Anesthesiology and Pain Medicine, College of medicine, Yeungnam University, Daemyung-Dong, Nam-Gu, Daegu, Republic of Korea


This study was designed to determine the optimal dose of remifentanil that can prevent the complications associated with the removal of LMA without delaying emergence.

Clinical Details

Official title: Optimal Effect-site Concentration of Remifentanil for Inhibiting Response to Laryngeal Mask Airway (LMA) Removal During Emergence From Sevoflurane-remifentanil Anesthesia

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention

Primary outcome: Number of Patients With Adverse Events Following LMA Removal

Detailed description: Patients were randomly assigned to one of four groups. All patients received a predetermined effect-site concentrations (Ce) of remifentanil by target-controlled infusion (TCI) according to their group assignments (R0, remifentanil Ce of 0 ng/ml; R0. 5, remifentanil Ce of 0. 5 ng/ml; R1. 0, remifentanil Ce of 1. 0 ng/ml; R1. 5, remifentanil Ce of 1. 5 ng/ml) from 10 minutes before the end of surgery to LMA removal. Airway complications (airway obstruction, desaturation, breath holding, and coughing), nausea, and vomiting were assessed during the emergence phase.


Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.


Inclusion Criteria:

- American Society of Anesthesiologists physical status 1 or 2

- undergoing lower extremity surgery under general anesthesia

Exclusion Criteria:

- suspected difficult airways

- respiratory disease (chronic obstructive pulmonary disease, upper respiratory


- body mass index > 30 kg/m2

- allergies to the study drugs

- a history of gastric reflux

Locations and Contacts

Additional Information

Starting date: July 2012
Last updated: August 21, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017